Payment overview · 2025
General Payments
$776.60
48 reported records · 13 companies
Healthcare provider profile · identity verified
Chaillie P Daniel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ST. FRANCISVILLE, LA · NPI 1972642312
Verified facts
What the public records show
CMS Open Payments records show Chaillie P Daniel, M.D. received $776.60 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.12 | 19.5% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.63 | 18.6% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.17 | 13.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.17 | 11.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.33 | 5.7% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.80 | 5.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.29 | 5.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.06 | 5.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.33 | 3.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.70 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.60 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.38 | 2.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.02 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $776.60 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.12 | 16 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $144.63 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.39 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $72.96 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $43.80 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $26.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.33 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 192 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 165 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 280 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
165 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
280 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1324 | 299 |
| Levothyroxine Sodium | Levothyroxine Sodium | 909 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 835 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 648 | 149 |
| Losartan Potassium | Losartan Potassium | 491 | 141 |
| Gabapentin | Gabapentin | 478 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 402 | 106 |
| Metformin Hcl Er | Metformin Hcl | 374 | 90 |
| Quetiapine Fumarate | Quetiapine Fumarate | 364 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 350 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 349 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 328 | 63 |
| Potassium Chloride | Potassium Chloride | 291 | 78 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 286 | 73 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 281 | 68 |
| Ozempic | Semaglutide | 280 | 64 |
| Lisinopril | Lisinopril | 273 | 57 |
| Furosemide | Furosemide | 268 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 60 |
| Metformin Hcl | Metformin Hcl | 254 | 54 |
| Omeprazole | Omeprazole | 234 | 50 |
| Montelukast Sodium | Montelukast Sodium | 219 | 54 |
| Clonazepam | Clonazepam | 217 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 47 |
| Carvedilol | Carvedilol | 207 | 45 |
| Lorazepam | Lorazepam | 198 | 37 |
| Eliquis | Apixaban | 192 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 188 | 53 |
| Sertraline Hcl | Sertraline Hcl | 177 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 35 |
| Trazodone Hcl | Trazodone Hcl | 173 | 31 |
| Mounjaro | Tirzepatide | 165 | 37 |
| Olanzapine | Olanzapine | 160 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 159 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 156 | 26 |
| Mirtazapine | Mirtazapine | 151 | 25 |
| Prednisone | Prednisone | 150 | 79 |
| Simvastatin | Simvastatin | 146 | 28 |
| Risperidone | Risperidone | 140 | 17 |
| Levetiracetam | Levetiracetam | 139 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 138 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 44 |
| Alprazolam | Alprazolam | 134 | 31 |
| Meloxicam | Meloxicam | 134 | 36 |
| Tramadol Hcl | Tramadol Hcl | 134 | 45 |
| Donepezil Hcl | Donepezil Hcl | 129 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 30 |
| Divalproex Sodium | Divalproex Sodium | 125 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 122 | 54 |
| Celecoxib | Celecoxib | 119 | 36 |
| Alendronate Sodium | Alendronate Sodium | 115 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 37 |
| Allopurinol | Allopurinol | 111 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 24 |
| Synthroid | Levothyroxine Sodium | 89 | 22 |
| Spironolactone | Spironolactone | 86 | 18 |
| Baclofen | Baclofen | 85 | 21 |
| Bupropion Xl | Bupropion Hcl | 85 | 21 |
| Terazosin Hcl | Terazosin Hcl | 84 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 16 |
| Januvia | Sitagliptin Phosphate | 81 | 13 |
| Haloperidol | Haloperidol | 79 | 16 |
| Buspirone Hcl | Buspirone Hcl | 77 | 15 |
| Finasteride | Finasteride | 77 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 18 |
| Ezetimibe | Ezetimibe | 74 | 23 |
| Memantine Hcl | Memantine Hcl | 74 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Aripiprazole | Aripiprazole | 70 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 14 |
| Latanoprost | Latanoprost | 65 | 12 |
| Topiramate | Topiramate | 65 | 16 |
| Jardiance | Empagliflozin | 62 | 13 |
| Clonidine Hcl | Clonidine Hcl | 60 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 14 |
| Cephalexin | Cephalexin | 58 | 39 |
| Enalapril Maleate | Enalapril Maleate | 57 | suppressed |
| Lactulose | Lactulose | 57 | 21 |
| Ondansetron Odt | Ondansetron | 57 | 29 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 48 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 14 |
| Humulin R | Insulin Regular, Human | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 12 |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Clozapine | Clozapine | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Glimepiride | Glimepiride | 40 | 12 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Nystatin | Nystatin | 37 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 35 | 11 |
| Fluphenazine Hcl | Fluphenazine Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Famotidine | Famotidine | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Novolin R | Insulin Regular, Human | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Olanzapine Odt | Olanzapine | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Atenolol | Atenolol | 28 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Mupirocin | Mupirocin | 27 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 23 |
| Diazepam | Diazepam | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $776.60 · 48 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, FANAPT, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, WATCHMAN Access System, WATCHMAN FLX, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error